205 related articles for article (PubMed ID: 35224496)
1. Profiling MAP kinase cysteines for targeted covalent inhibitor design.
Liu R; Verma N; Henderson JA; Zhan S; Shen J
RSC Med Chem; 2022 Jan; 13(1):54-63. PubMed ID: 35224496
[TBL] [Abstract][Full Text] [Related]
2. Reactivities of the Front Pocket N-Terminal Cap Cysteines in Human Kinases.
Liu R; Zhan S; Che Y; Shen J
J Med Chem; 2022 Jan; 65(2):1525-1535. PubMed ID: 34647463
[TBL] [Abstract][Full Text] [Related]
3. Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors.
Liu R; Yue Z; Tsai CC; Shen J
J Am Chem Soc; 2019 Apr; 141(16):6553-6560. PubMed ID: 30945531
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the ERK Pathway Cysteinome for Targeted Covalent Inhibition of RAF and MEK Kinases.
Romany A; Liu R; Zhan S; Clayton J; Shen J
J Chem Inf Model; 2023 Apr; 63(8):2483-2494. PubMed ID: 37022803
[TBL] [Abstract][Full Text] [Related]
5. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.
Zhao Z; Liu Q; Bliven S; Xie L; Bourne PE
J Med Chem; 2017 Apr; 60(7):2879-2889. PubMed ID: 28326775
[TBL] [Abstract][Full Text] [Related]
6. How Reactive are Druggable Cysteines in Protein Kinases?
Awoonor-Williams E; Rowley CN
J Chem Inf Model; 2018 Sep; 58(9):1935-1946. PubMed ID: 30118220
[TBL] [Abstract][Full Text] [Related]
7. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
Suplatov D; Kopylov K; Sharapova Y; Švedas V
J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
[TBL] [Abstract][Full Text] [Related]
8. X-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitors.
Kuglstatter A; Ghate M; Tsing S; Villaseñor AG; Shaw D; Barnett JW; Browner MF
Bioorg Med Chem Lett; 2010 Sep; 20(17):5217-20. PubMed ID: 20655210
[TBL] [Abstract][Full Text] [Related]
9. Distinct binding modes of a benzothiazole derivative confer structural bases for increasing ERK2 or p38α MAPK selectivity.
Hasegawa S; Yoshida M; Nagao H; Sugiyama H; Sawa M; Kinoshita T
Biochem Biophys Res Commun; 2024 Apr; 704():149707. PubMed ID: 38428305
[TBL] [Abstract][Full Text] [Related]
10. Role of a cysteine residue in the active site of ERK and the MAPKK family.
Ohori M; Kinoshita T; Yoshimura S; Warizaya M; Nakajima H; Miyake H
Biochem Biophys Res Commun; 2007 Feb; 353(3):633-7. PubMed ID: 17194451
[TBL] [Abstract][Full Text] [Related]
11. Reactive-cysteine profiling for drug discovery.
Maurais AJ; Weerapana E
Curr Opin Chem Biol; 2019 Jun; 50():29-36. PubMed ID: 30897495
[TBL] [Abstract][Full Text] [Related]
12. Selectivity of docking sites in MAPK kinases.
Bardwell AJ; Frankson E; Bardwell L
J Biol Chem; 2009 May; 284(19):13165-73. PubMed ID: 19196711
[TBL] [Abstract][Full Text] [Related]
13. Predicting Reactive Cysteines with Implicit-Solvent-Based Continuous Constant pH Molecular Dynamics in Amber.
Harris RC; Liu R; Shen J
J Chem Theory Comput; 2020 Jun; 16(6):3689-3698. PubMed ID: 32330035
[TBL] [Abstract][Full Text] [Related]
14. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Covalent Pyrazolopyrimidine-MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7).
Wolle P; Engel J; Smith S; Goebel L; Hennes E; Lategahn J; Rauh D
J Med Chem; 2019 Jun; 62(11):5541-5546. PubMed ID: 31083997
[TBL] [Abstract][Full Text] [Related]
16. GPU-Accelerated Implementation of Continuous Constant pH Molecular Dynamics in Amber: p
Harris RC; Shen J
J Chem Inf Model; 2019 Nov; 59(11):4821-4832. PubMed ID: 31661616
[TBL] [Abstract][Full Text] [Related]
17. [Advances in applications of activity-based chemical probes in the characterization of amino acid reactivities].
Li J; Wang G; Ye M; Qin H
Se Pu; 2023 Jan; 41(1):14-23. PubMed ID: 36633073
[TBL] [Abstract][Full Text] [Related]
18. Seven cysteine-deficient mutants depict the interplay between thermal and chemical stabilities of individual cysteine residues in mitogen-activated protein kinase c-Jun N-terminal kinase 1.
Nakaniwa T; Fukada H; Inoue T; Gouda M; Nakai R; Kirii Y; Adachi M; Tamada T; Segawa S; Kuroki R; Tada T; Kinoshita T
Biochemistry; 2012 Oct; 51(42):8410-21. PubMed ID: 23020677
[TBL] [Abstract][Full Text] [Related]
19. JSAP1, a novel jun N-terminal protein kinase (JNK)-binding protein that functions as a Scaffold factor in the JNK signaling pathway.
Ito M; Yoshioka K; Akechi M; Yamashita S; Takamatsu N; Sugiyama K; Hibi M; Nakabeppu Y; Shiba T; Yamamoto KI
Mol Cell Biol; 1999 Nov; 19(11):7539-48. PubMed ID: 10523642
[TBL] [Abstract][Full Text] [Related]
20. Insights into MAPK p38alpha DFG flip mechanism by accelerated molecular dynamics.
Filomia F; De Rienzo F; Menziani MC
Bioorg Med Chem; 2010 Sep; 18(18):6805-12. PubMed ID: 20724167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
